Two researchers with the University of Pittsburgh Cancer Institute have been awarded research grants by the Melanoma Research Alliance (MRA). Hussein Tawbi, MD, PhD, and Hassane M. Zarour, MD, were two of 49 researchers at leading academic research institutions around the world to share in over $9.6 million in MRA grants to develop improved means to prevent, detect and treat melanoma, one of the fastest growing cancers. Both are members of the SPORE-funded Melanoma and Skin Cancer Program at UPCI.
Dr. Tawbi, assistant professor in the Department of Medicine at the University of Pittsburgh School of Medicine, is one of three principal investigators awarded the Team Science Award to continue their study of the safety and efficacy of the selective BRAF inhibitor drabafenib in melanoma patients with brain metastases. Dr. Tawbi and researchers from University of Texas M.D. Anderson Cancer Center and Melanoma Institute Australia will receive $900,000 over three years from the MRA.
